Cost-effectiveness of Antihypertensive Guidelines in Finland
Author Information
Author(s): Neill Booth, Antti Jula, Pasi Aronen, Minna Kaila, Timo Klaukka, Katriina Kukkonen-Harjula, Antti Reunanen, Pekka Rissanen, Harri Sintonen, Marjukka Mäkelä
Primary Institution: Tampere School of Public Health, University of Tampere
Hypothesis
Can the 2002 Finnish evidence-based Current Care Guidelines for hypertension be considered cost-effective compared to prior clinical practice?
Conclusion
The ACCG scenario is likely to reduce costs and increase life-years compared to the PCP scenario in many subgroups.
Supporting Evidence
- The ACCG scenario is cost-saving and more effective in most subgroups.
- Implementation of the ACCG is expected to save 498 million euros and produce 49,000 extra life-years.
- Over half of the Finnish population aged 40-74 has elevated blood pressure.
Takeaway
This study shows that following new guidelines for treating high blood pressure can save money and help people live longer.
Methodology
A decision analytic model was used to compare the ACCG and PCP scenarios using data from national registers and surveys.
Potential Biases
The study assumes full adherence to the guidelines, which may not be realistic in practice.
Limitations
The model's assumptions may not fully reflect real-world adherence to guidelines, and the analysis does not account for all potential costs and outcomes.
Participant Demographics
Participants were Finnish individuals aged 40-74 without cardiovascular diseases or diabetes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website